Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

Industries Ltd ADR (NYSE: TEVA) surged 6.2% while Alvotech SA (NASDAQ: ALVO) climbed 3.5% in premarket trading today, ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...

“Interchangeability of Selarsdi with Stelara will further enable increased access for US patients to more affordable treatment options and contribute to lowering health care costs, which is an ...

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has reported that the FDA has approved the biosimilar treatment ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

US subsidiary and Iceland-based Alvotech (Nasdaq: ALVO) today announced that the US Food and Drug Administration (FDA) has ...

Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA).

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...